FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 11:34:58 2024-05-17 EDT | ||
| 4.17 EUR | +9.16% |
|
| Current month | +125.41% | ||
| 1 month | +116.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 4.17 | +9.16% |
| 24-05-16 | 3.82 | +3.52% |
| 24-05-15 | 3.69 | +20.59% |
| 24-05-14 | 3.06 | -4.67% |
| 24-05-13 | 3.21 | +10.69% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 11:34 am
More quotesStatic data
| Product type | Productos Exóticos |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SN7D86 |
| ISIN | DE000SN7D862 |
| Date issued | 2022-07-28 |
| Strike | 288.6 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.35 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.82 € |
|---|---|
| Lowest since issue | 1.26 € |
| Spread | 0.13 € |
| Spread % | 2.90% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
